MedTrace Logo

Zinc Supplementation With Botulinum Toxin for Overactive Bladder

NCT07405554 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-02-27

No results posted yet for this study

Summary

This randomized, double-blind, placebo-controlled trial evaluates whether oral zinc plus phytase supplementation modifies clinical response to intradetrusor botulinum toxin injection in patients with overactive bladder. Participants will receive either zinc plus phytase supplementation or matching placebo for five days prior to intradetrusor botulinum toxin injection. Participants will be followed for six months after treatment to assess need for repeat botulinum toxin injection, urinary symptoms, and patient-reported outcomes related to overactive bladder.

Conditions

  • Overactive Bladder (OAB)

Interventions

DRUG

Zinc Citrate Oral Capsule

Zinc citrate 50mg combined with 7,500 phytase units in an oral capsule

DRUG

Placebo

Placebo oral capsule

Sponsors & Collaborators

  • Endeavor Health

    lead OTHER

Principal Investigators

  • Ghazaleh Rostami Nia, MD · Endeavor Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-26
Primary Completion
2026-05-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07405554 on ClinicalTrials.gov